Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $12.5

Author: Benzinga Newsdesk | September 25, 2025 07:04am

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ: AYTU) with a Buy and raises the price target from $12 to $12.5.

Posted In: AYTU